Amyris Inc  

(Public, NASDAQ:AMRS)   Watch this stock  
Find more results for AMRS
0.458
+0.019 (4.21%)
Aug 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.43 - 0.48
52 week 0.31 - 2.57
Open 0.44
Vol / Avg. 0.00/2.47M
Mkt cap 115.07M
P/E     -
Div/yield     -
EPS -0.88
Shares 235.02M
Beta 0.95
Inst. own 40%
Nov 3, 2016
Q3 2016 Amyris Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Amyris Inc Earnings Call - Webcast
Aug 4, 2016
Q2 2016 Amyris Inc Earnings Release
Jun 30, 2016
Amyris Inc Conference Call to Discuss the Partnership with Ginkgo Bioworks - Webcast
Jun 9, 2016
Amyris Inc at Singular Research San Francisco Spring Select Conference
Jun 7, 2016
Amyris Inc at Stifel Technology Internet & Media Conference - Webcast
Jun 1, 2016
Amyris Inc at Cowen Technology, Media & Telecom Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -141.33% -626.21%
Operating margin -242.83% -438.25%
EBITD margin - -280.86%
Return on average assets -52.33% -132.71%
Return on average equity - -
Employees 418 -
CDP Score - -

Address

5885 Hollis St Ste 100
EMERYVILLE, CA 94608-2405
United States - Map
+1-510-4500761 (Phone)
+1-510-2252645 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

Officers and directors

John G. Melo President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Raffi Asadorian Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Joel Cherry Ph.D. President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Karen D. Rohde Chief Human Resources Officer
Bio & Compensation  - Reuters
Chris Jaenike Interim General Counsel
Bio & Compensation  - Reuters
Philippe Boisseau Director
Age: 53
Bio & Compensation  - Reuters
Margaret H. Georgiadis Director
Age: 52
Bio & Compensation  - Reuters
Abraham Klaeijsen Director
Bio & Compensation  - Reuters
Patrick Y. Yang Director
Bio & Compensation  - Reuters
Abdullah Bin Khalifa Al Thani Independent Director
Age: 55
Bio & Compensation  - Reuters